Details
| Stereochemistry | UNKNOWN |
| Molecular Formula | C21H25ClN2O4S |
| Molecular Weight | 436.952 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C2=C(C=CC=C2)C(NCCCCCCC(O)=O)C3=CC=C(Cl)C=C3S1(=O)=O
InChI
InChIKey=JICJBGPOMZQUBB-UHFFFAOYSA-N
InChI=1S/C21H25ClN2O4S/c1-24-18-9-6-5-8-16(18)21(23-13-7-3-2-4-10-20(25)26)17-12-11-15(22)14-19(17)29(24,27)28/h5-6,8-9,11-12,14,21,23H,2-4,7,10,13H2,1H3,(H,25,26)
TIANEPTINE, a tricyclic antidepressant, is a drug used for the treatment of the major depressive disorder. It was discovered by The French Society of Medical Research in the 1980s. Unlike other tricyclic antidepressants, TIANEPTINE is a selective serotonin reuptake enhancer with minimal effects on norepinephrine and dopamine uptake. Also, it is a full agonist at the mu-opioid and delta-opioid receptors with no effect at the kappa-opioid receptors. Selective mu-opioid agonists typically induce euphoria, which may contribute to TIANEPTINE's antidepressant effect. It is marketed as Coaxil/Stablon in many European countries, but it is not available in the US.
CNS Activity
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Asthma, asthma medication and autonomic nervous system dysfunction. | 2001 Nov |
|
| Tianeptine and fluoxetine in major depression: a 6-week randomised double-blind study. | 2002 Aug |
|
| Synaptic plasticity and tianeptine: structural regulation. | 2002 Jul |
|
| [Efficacy and acceptability of tianeptine and sertraline in the acute treatment phase of depression]. | 2002 Jul-Aug |
|
| The antidepressant tianeptine persistently modulates glutamate receptor currents of the hippocampal CA3 commissural associational synapse in chronically stressed rats. | 2002 Sep |
|
| Enhancement of stress-induced pituitary hormone release and cardiovascular activation by antidepressant treatment in healthy men. | 2002 Sep |
|
| The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. | 2003 |
|
| State markers of depression in sleep EEG: dependency on drug and gender in patients treated with tianeptine or paroxetine. | 2003 Feb |
|
| Tianeptine may be a useful adjunct in the treatment of alcohol dependence of adolescents. | 2003 Jan |
|
| Antidepressants: psychiatrists' opinions and clinical practice. | 2003 Jul |
|
| [A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression]. | 2003 Jul-Aug |
|
| Evaluation of cognitive function of fluoxetine, sertraline and tianeptine in isolation and chronic unpredictable mild stress-induced depressive Wistar rats. | 2003 Nov |
|
| [Misuse of tianeptine: five cases of abuse]. | 2003 Nov |
|
| Prenatal stress in rats predicts immobility behavior in the forced swim test. Effects of a chronic treatment with tianeptine. | 2003 Nov 7 |
|
| Behavioural effects of thieno and pyrazolo [2,1] benzothiazepine derivatives in mice. | 2004 |
|
| [Depressions and disorders of depressive spectrum in general medical practice. Results of the COMPAS program]. | 2004 |
|
| Trends in the development of new antidepressants. Is there a light at the end of the tunnel? | 2004 Apr |
|
| The effects of tianeptine or paroxetine on 35% CO2 provoked panic in panic disorder. | 2004 Dec |
|
| Alterations of neuroplasticity in depression: the hippocampus and beyond. | 2004 Dec |
|
| Acute stress-induced changes in hippocampal/prefrontal circuits in rats: effects of antidepressants. | 2004 Feb |
|
| Chronic administration of tianeptine balances lipopolysaccharide-induced expression of cytokines in the spleen and hypothalamus of rats. | 2004 Jul |
|
| Differential regulation of variant glucocorticoid receptor mRNAs in the rat hippocampus by the antidepressant fluoxetine. | 2004 Oct 22 |
|
| [Coaxil therapy of affective disorders in brain vascular pathology]. | 2005 |
|
| [Coaxil treatment of primary headaches comorbid with depression]. | 2005 |
|
| Regulation of hippocampal gene expression is conserved in two species subjected to different stressors and antidepressant treatments. | 2006 Feb 1 |
Patents
Sample Use Guides
Using radioligand binding and cell-based functional assays, including bioluminescence resonance energy transfer-based assays for G-protein activation and cAMP accumulation, tianeptine was identified as an efficacious mu-opioid receptor agonist (Ki of 383+/-183 nM and EC50 of 194+/-70 nM). Tianeptine was also a full delta-opioid receptor agonist, although with much lower potency (EC50 of 37.4+/-11.2 uM for G-protein activation). In contrast, tianeptine was inactive at the kappa-opioid receptor.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
XV6773012I
Created by
admin on Sat Dec 16 10:25:43 GMT 2023 , Edited by admin on Sat Dec 16 10:25:43 GMT 2023
|
PRIMARY | |||
|
191172-75-5
Created by
admin on Sat Dec 16 10:25:43 GMT 2023 , Edited by admin on Sat Dec 16 10:25:43 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
